Javascript must be enabled to continue!
Protective Effects of Pentoxyfilline In Renal Toxicity After Methotrexate Administration
View through CrossRef
Abstract
Abstract 4950
Methotrexate (MTX), a folic acid antagonist, is widely used as a treatment for malignancies as well as in the treatment of various inflammatory and autoimmune disorders. Nephrotoxicity is an important side-effect of this drug. Prevention and treatment of MTX-induced renal dysfunction are essential to prevent potentially life-threatening MTX-associated toxicities, Pentoxifylline(PTX) is an anti-inflammatory and anti-oxidant agent and we hypothesized that pentoxifylline may affords renal protection by down regulating TNF-α as well as by improving cellular anti-oxidant activity.
Forty five male wistar rats were assigned to 3 groups of 15 animals each: Group 1: control group (0.9% saline). Group 2: MTX; injected with 20mg/kg MTX intra peritoneal. Group 3: MTX+PA; injected intraperitoneally (i.p.) MTX (20 mg/kg) + PTX (50mg/kg) intraperitoneally. PTX was administered since 3 days before MTX administration and continued for 6 days. After 6 days rats were anesthetized and serum sampled and renal tissue removed for biochemical and histological evaluation.
Data showed that glutathione peroxidase (GPx), superoxide dismutase (SOD)activities were lower in PTX+NTX group comparing to MTX group significantly(p<0.05). Renal tissue injury index and percent of TUNEL positive cells, renal tissue malondialdehyde (MDA) levels and plasma BUN(Blood Urea Nitrogen) and creatinine (Cr) and Tumor necrosis factor- Alpha(TNF-α) levels were higher in MTX group comparing to MTX+PTX group significantly (p<0.05).
In conclusions, it has been suggested that PTX may be a promising drug against MTX-induced renal damage and oxidative renal stress. Further studies are warranted to define the exact mechanism of the protecting effect of PTX on MTX-induced nephrotoxicity and the optimum dosage of this compound. In addition, these data indicate that the activities of GPX and SOD enzymes content in rat kidneys may play a role in the pathogenesis of MTX-damage. In our study, the increased level of tissue MDA and serum TNF-α level together may be suggested that the underlying mechanism is related to direct toxicity of MTX rather than blockage in folate synthesis in rat kidneys. PTX administration also attenuated renal tissue injury and number of apoptic cells and suppressed elevation of BUN and Cr levels; however, further studies are essential to elucidate the exact mechanisms of MTX-induced renal toxicity, and protection and the effect of PTX.
Disclosures:
Kermani: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Employment, Membership on an entity's Board of Directors or advisory committees, Research Funding. Hajipour: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Research Funding. Kermani: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Research Funding. Ahmadi Asl: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Research Funding. Roshanghar: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Research Funding. Khodadadi: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Research Funding.
American Society of Hematology
Title: Protective Effects of Pentoxyfilline In Renal Toxicity After Methotrexate Administration
Description:
Abstract
Abstract 4950
Methotrexate (MTX), a folic acid antagonist, is widely used as a treatment for malignancies as well as in the treatment of various inflammatory and autoimmune disorders.
Nephrotoxicity is an important side-effect of this drug.
Prevention and treatment of MTX-induced renal dysfunction are essential to prevent potentially life-threatening MTX-associated toxicities, Pentoxifylline(PTX) is an anti-inflammatory and anti-oxidant agent and we hypothesized that pentoxifylline may affords renal protection by down regulating TNF-α as well as by improving cellular anti-oxidant activity.
Forty five male wistar rats were assigned to 3 groups of 15 animals each: Group 1: control group (0.
9% saline).
Group 2: MTX; injected with 20mg/kg MTX intra peritoneal.
Group 3: MTX+PA; injected intraperitoneally (i.
p.
) MTX (20 mg/kg) + PTX (50mg/kg) intraperitoneally.
PTX was administered since 3 days before MTX administration and continued for 6 days.
After 6 days rats were anesthetized and serum sampled and renal tissue removed for biochemical and histological evaluation.
Data showed that glutathione peroxidase (GPx), superoxide dismutase (SOD)activities were lower in PTX+NTX group comparing to MTX group significantly(p<0.
05).
Renal tissue injury index and percent of TUNEL positive cells, renal tissue malondialdehyde (MDA) levels and plasma BUN(Blood Urea Nitrogen) and creatinine (Cr) and Tumor necrosis factor- Alpha(TNF-α) levels were higher in MTX group comparing to MTX+PTX group significantly (p<0.
05).
In conclusions, it has been suggested that PTX may be a promising drug against MTX-induced renal damage and oxidative renal stress.
Further studies are warranted to define the exact mechanism of the protecting effect of PTX on MTX-induced nephrotoxicity and the optimum dosage of this compound.
In addition, these data indicate that the activities of GPX and SOD enzymes content in rat kidneys may play a role in the pathogenesis of MTX-damage.
In our study, the increased level of tissue MDA and serum TNF-α level together may be suggested that the underlying mechanism is related to direct toxicity of MTX rather than blockage in folate synthesis in rat kidneys.
PTX administration also attenuated renal tissue injury and number of apoptic cells and suppressed elevation of BUN and Cr levels; however, further studies are essential to elucidate the exact mechanisms of MTX-induced renal toxicity, and protection and the effect of PTX.
Disclosures:
Kermani: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Employment, Membership on an entity's Board of Directors or advisory committees, Research Funding.
Hajipour: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Research Funding.
Kermani: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Research Funding.
Ahmadi Asl: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Research Funding.
Roshanghar: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Research Funding.
Khodadadi: Hematology and Oncology Research Center, Tabriz University of Medical Sciences: Research Funding.
Related Results
E069 Preventing co-prescription of methotrexate with trimethoprim containing medicines in paediatric rheumatology
E069 Preventing co-prescription of methotrexate with trimethoprim containing medicines in paediatric rheumatology
Abstract
Background/Aims
Co-prescribing of low-dose methotrexate and trimethoprim or co-trimoxazole is associated with bo...
Comparison of Sodium Bicarbonate and Lactated Ringers Hydration for High-dose Methotrexate Chemotherapy in Children
Comparison of Sodium Bicarbonate and Lactated Ringers Hydration for High-dose Methotrexate Chemotherapy in Children
Background:
High-dose methotrexate is part of the treatment of pediatric cancers. To reduce the risk of toxicity, supportive measures, including hydration and alkaliniz...
Teratogen update: Methotrexate
Teratogen update: Methotrexate
AbstractMethotrexate and aminopterin are folic acid antagonists that inhibit dihydrofolate reductase, resulting in a block in the synthesis of thymidine and inhibition of DNA synth...
Influence of ABCB1 3435C>T Polymorphism on Methotrexate Safety in Patients with Psoriasis — A Secondary Publication
Influence of ABCB1 3435C>T Polymorphism on Methotrexate Safety in Patients with Psoriasis — A Secondary Publication
Background: Methotrexate is a highly effective systemic treatment for moderate to severe psoriasis, but drug toxicity may limit its use. Recent evidence suggests that it is necessa...
Toxicity evaluation of ultra-diluted Methotrexate (12c&30c): An acute and subacute Oral toxicity study in animals
Toxicity evaluation of ultra-diluted Methotrexate (12c&30c): An acute and subacute Oral toxicity study in animals
Abstract
Purpose
Autoimmune diseases exhibit active and remission phases. Tissues may retain an "inflammatory memory," increasing relapse risk after stopping treatment, nec...
Liver biopsy in methotrexate-treated psoriatics-a re-evalution
Liver biopsy in methotrexate-treated psoriatics-a re-evalution
Two-hundred and eighty-six liver biopsies were performed in 139 psoriatics on treatment or considered for treatment with methotrexate. In 56 psoriatics included in this study both ...
ASSA13-14-12 Association of Renal Artery Variations and Renal Artery Stenosis, Impaired Renal Function, Plasma Renin Activity
ASSA13-14-12 Association of Renal Artery Variations and Renal Artery Stenosis, Impaired Renal Function, Plasma Renin Activity
Objectives
To compare the prevalence of hemodynamically significant stenosis between renal arteries with and without variations in resistant hypertensive patients...
Evaluating the effect of methotrexate on the rate of renal fibrosis by elastography and fibrosis-related gene expression
Evaluating the effect of methotrexate on the rate of renal fibrosis by elastography and fibrosis-related gene expression
Methotrexate is mainly used to treat diseases such as rheumatoid arthritis (RA), but its potential for nephrotoxicity has always been a significant concern on the use of this medic...

